The Effect of a Probiotic Intervention in Healthy Subjects and Patients With Atopic Dermatitis
NCT ID: NCT00550472
Last Updated: 2008-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2004-12-31
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
As a precondition for participating in this study, the subjects were provided information in writing and verbally about the details of the study. Informed consent was obtained from all volunteers. Before the beginning of the study, all participants were subject to a medical examination in the Clinic for Dermatology and Dermatologic Allergology of the Friedrich Schiller University Jena. The AD was diagnosed according to the atopy-score of Diepgen. Severity of eczema was evaluated by using the SCORAD score. A skin prick test was performed for the exclusion of type 1 sensitivity to cow's milk.
The study was designed as a placebo-controlled and cross-over study. After a 3-week run-in period the 30 participants (15 healthy subjects and 15 patients with AD) were randomized to receive either 200 ml/d of a probiotic drink containing L. paracasei Lpc-37, L. acidophilus 74-2 and B. lactis 420 or 200 ml/d of a placebo drink for 8 weeks. After a 2-week washout period the intervention was crossed between the groups and the respective products were consumed for another 8 weeks followed by a 2-week washout period. Venous blood and fresh stool samples were collected before the beginning and at the end of each period. In AD patients the Scoring of atopic dermatitis (SCORAD) was assessed by the same physician every 4 weeks and 2 weeks after the wash-out period, respectively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic
intervention
probiotics
Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
probiotics
Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No allergic asthma
* No allergic rhinoconjunctivitis
* No food allergies
* Exclusion of atopic diathesis (\< 7 points in Erlangen atopy score)
Patients with AD:
* Clear diagnosis of atopic dermatitis (\> 10 points in the Erlangen atopy score) or flexural eczema or pruritis for at least 12 months (recidivating or permanent)
* SCORAD 5-30 (minor or medium AD)
* Willingness to apply for the duration of the study exclusively the cosmetic products recommended by the accompanying doctor and to use the recommended class II corticosteroid (Advantan) as further therapy of AD (for example during an episode)
Exclusion Criteria
* Immune suppressive or cytostatic therapy or systemic steroids \< 1 month before the first intake
* Phototherapy or systemic therapy of AD \< 1 month before the first intake
* Active infections of the skin
* Relevant asthma disease, which must be treated with inhalative corticoids (FEV1 \< 70 %)
* Patients with an indigestibility of/allergy against the components of milk/lactose intolerance (previously known or detected in the allergy test)
* Patients under long-term treatment with systemic steroids, depot steroids, long-acting antihistamines, tranquilizers, psychopharmaceuticals
* Intake of antihistamines, psychopharmaceuticals with antihistaminic effect and application of steroid containing cream to the forearms within the past 7 days before prick testing resp. treatment of the patient with Astemizol (Hismanal) within 4 weeks before the test. Such patients must be excluded from the study because of the long half-life of the medicament.
* Acute or chronic symptomatic heart disease or severe internistic diseases
* Autoimmune diseases, immune deficiencies (including immune suppressive treatment)
* Immune-complex-induced immunopathies or malignant tumors
* Abuse of alcohol, drugs or medicaments
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Jena
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dept. of Nutritional Physiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gerhard Jahreis, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University of Jena, Dept. of Nutritional Physiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Jena, Institute of Nutrition, Department of Nutritional Physiology
Jena, Thuringia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LSEP H18-05
Identifier Type: -
Identifier Source: org_study_id